NA
VKTX icon

NewEdge Advisors’s Viking Therapeutics VKTX Stock Holding History

NewEdge Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645K Buy
16,533
+577
+4% +$18.6K ﹤0.01% 1974
2026
Q1 		$519K Sell
15,956
-791
-5% -$25.4K ﹤0.01% 1963
2025
Q4 		$589K Buy
16,747
+139
+0.8% +$4.92K ﹤0.01% 1853
2025
Q3 		$436K Sell
16,608
-1,147
-6% -$34.2K ﹤0.01% 1914
2025
Q2 		$471K Buy
17,755
+15,418
+660% +$406K ﹤0.01% 1732
2025
Q1 		$56.4K Buy
2,337
+269
+13% +$8.5K ﹤0.01% 2515
2024
Q4 		$83.2K Buy
2,068
+1,076
+108% +$61.4K ﹤0.01% 2343
2024
Q3 		$62.8K Sell
992
-10,532
-91% -$618K ﹤0.01% 2360
2024
Q2 		$611K Sell
11,524
-2,093
-15% -$137K ﹤0.01% 1301
2024
Q1 		$1.12M Buy
13,617
+13,023
+2,192% +$579K 0.01% 951
2023
Q4 		$11.1K Buy
+594
New +$7.77K ﹤0.01% 2800

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

NewEdge Advisors's VKTX Position: Q2 2026 in Review

NewEdge Advisors increased its Viking Therapeutics (VKTX) stake by 3.6% in Q2 2026, buying an estimated $18.6K and bringing the position to 16,533 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #1974.

NewEdge Advisors first reported a position in VKTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.12M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • NewEdge Advisors held 16,533 shares of Viking Therapeutics worth $645K as of Q2 2026.
  • NewEdge Advisors bought 577 Viking Therapeutics shares in Q2 2026, an estimated $18.6K.
  • Viking Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1974 holding.
  • NewEdge Advisors first reported a position in Viking Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • NewEdge Advisors's Viking Therapeutics position peaked at $1.12M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.